Hologic Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 522 shares of the business’s stock in a transaction on Monday, November 7th. The shares were sold at an average price of $38.53, for a total transaction of $20,112.66. Following the completion of the transaction, the vice president now directly owns 9,839 shares of the company’s stock, valued at approximately $379,096.67. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Karleen Marie Oberton also recently made the following trade(s):

  • On Tuesday, November 8th, Karleen Marie Oberton sold 984 shares of Hologic stock. The shares were sold at an average price of $38.57, for a total transaction of $37,952.88.
  • On Monday, October 10th, Karleen Marie Oberton sold 31,470 shares of Hologic stock. The shares were sold at an average price of $40.00, for a total transaction of $1,258,800.00.

Hologic Inc. (NASDAQ:HOLX) opened at 37.16 on Thursday. Hologic Inc. has a 12-month low of $31.84 and a 12-month high of $41.66. The company has a market capitalization of $10.31 billion, a PE ratio of 32.03 and a beta of 1.13. The firm has a 50-day moving average of $38.13 and a 200 day moving average of $36.58.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.02. The firm earned $726.80 million during the quarter, compared to analysts’ expectations of $721.52 million. Hologic had a net margin of 11.68% and a return on equity of 26.76%. The business’s revenue was up 3.4% on a year-over-year basis. During the same period last year, the company earned $0.43 earnings per share. Analysts forecast that Hologic Inc. will post $2.14 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Several brokerages have recently issued reports on HOLX. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Thursday, July 28th. Leerink Swann reissued an “outperform” rating and issued a $46.00 price target on shares of Hologic in a report on Monday, October 3rd. Barclays PLC reissued a “buy” rating and issued a $45.00 price target on shares of Hologic in a report on Thursday, November 3rd. Zacks Investment Research lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Finally, Evercore ISI raised shares of Hologic from a “hold” rating to a “buy” rating and upped their target price for the stock from $38.00 to $42.00 in a research note on Thursday, July 28th. Six investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Hologic presently has a consensus rating of “Buy” and a consensus target price of $43.20.

Hedge funds and other institutional investors have recently modified their holdings of the stock. American International Group Inc. boosted its position in shares of Hologic by 12.6% in the third quarter. American International Group Inc. now owns 93,833 shares of the company’s stock worth $3,644,000 after buying an additional 10,532 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Hologic by 0.8% in the third quarter. California State Teachers Retirement System now owns 595,624 shares of the company’s stock worth $23,128,000 after buying an additional 5,000 shares in the last quarter. State of Tennessee Treasury Department boosted its position in shares of Hologic by 104.2% in the third quarter. State of Tennessee Treasury Department now owns 395,759 shares of the company’s stock worth $15,367,000 after buying an additional 201,954 shares in the last quarter. Holland Capital Management LLC acquired a new position in shares of Hologic during the third quarter worth about $26,035,000. Finally, Tamarack Advisers LP boosted its position in shares of Hologic by 16.4% in the third quarter. Tamarack Advisers LP now owns 390,000 shares of the company’s stock worth $15,035,000 after buying an additional 55,000 shares in the last quarter. Hedge funds and other institutional investors own 94.61% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.